Expression profiles of inhibitor of growth protein 2 in normal and cancer tissues: An immunohistochemical screening analysis

Zhao,Shuang; Yang,Xue‑Feng; Gou,Wen‑Feng; Lu,Hang; Li,Hua; Zhu,Zhi‑Tu; Sun,Hong‑Zhi; Zheng,Hua‑Chuan

doi:10.3892/mmr.2015.4723

Expression profiles of inhibitor of growth protein 2 in normal and cancer tissues: An immunohistochemical screening analysis

Authors:
- Shuang Zhao
- Xue‑Feng Yang
- Wen‑Feng Gou
- Hang Lu
- Hua Li
- Zhi‑Tu Zhu
- Hong‑Zhi Sun
- Hua‑Chuan Zheng
View Affiliations

Affiliations: Cancer Center and Key Laboratory of Brain and Spinal Cord Injury of Liaoning Province, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: December 28, 2015 https://doi.org/10.3892/mmr.2015.4723
Pages: 1881-1887

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibitor of growth protein 2 (ING2) has an important role in the regulation of chromatin remodeling, cell proliferation, cell‑cycle arrest, senescence and apoptosis. The present study performed an immunohistochemical analysis for expression profiling of ING2 protein in an array of tissues comprising normal mouse and human tissues, as well as human hepatocellular (n=62), renal clear cell (n=62), pancreatic (n=62), esophageal squamous cell (n=45), cervical squamous cell (n=31), breast (n=144), gastric (n=196), colorectal (n=96), ovarian (n=208), endometrial (n=96) and lung (n=192) carcinoma tissues. In mouse tissues, ING2 was detected in the nuclei and cytoplasm of the glandular epithelium of breast, hepatocytes, intestine, bronchium and alveoli, as well as the squamous epithelium of skin and glomeruli, and in myocardial cells, while it was located in the cytoplasm of renal tubules and striated muscle cells. ING2 protein was scattered in the brain and spleen. In human tissues, ING2 protein was principally distributed in the cytoplasm, while in it was present in the cytoplasm and nuclei in the stomach, intestine, cervix, endometrium trachea, breast and pancreas. The nuclear location of ING2 in the stomach was more prominent than that in the cytoplasm. High ING2 immunoreactivity was detected in the tongue, stomach, skin, pancreas, cervix and breast, whereas weakly in the brain stem, thymus, thyroid, lung, striated muscle, testis, bladder and ovary. In total, 617 out of 1,194 of the tested cancer tissues (51.7%) were ING2-positive. In most cases, ING2 expression was found to be restricted to the cytoplasm of all cancer tissues, while in certain cancer types, including renal clear cell, ovarian and colorectal carcinoma, it was occasionally present in the nuclei. Among the cancer tissues examined, ING2 was most frequently expressed in breast cancer (67.4%) and gynecological cancer types, including ovarian cancer (61.5%) and endometrial cancer (57.3%). Compared with that in the respective normal tissues, ING2 expression in breast cancer tissues was decreased, while that in cervical cancer was upregulated in the nuclei as well as the cytoplasm. In endometrial cancer, expression of ING2 was increased in the nuclei and declined in the cytoplasm compared with that in the normal endometrium. ING2‑positive cases were less frequent for renal clear cell carcinoma (17.7%). The results of the present study suggested that ING2 may be involved in the repair and regeneration of organs or tissues and is associated with breast and gynecological carcinogenesis.

View Figures

View References

1	Guérillon C, Larrieu D and Pedeux R: ING1 and ING2: Multifaceted tumor suppressor genes. Cell Mol Life Sci. 70:3753–3772. 2013. View Article : Google Scholar : PubMed/NCBI
2	Pedeux R, Sengupta S, Shen JC, Demidov ON, Saito S, Onogi H, Kumamoto K, Wincovitch S, Garfeld SH, McMenamin M, et al: ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol. 25:6639–6648. 2005. View Article : Google Scholar : PubMed/NCBI
3	Bua DJ, Martin GM, Binda O and Gozani O: Nuclear phosphatidylinositol-5-phosphate regulates ING2 stability at discrete chromatin targets in response to DNA damage. Sci Rep. 3:21372013. View Article : Google Scholar : PubMed/NCBI
4	Larrieu D, Ythier D, Brambilla C and Pedeux R: ING2 controls the G1 to S-phase transition by regulating p21 expression. Cell Cycle. 9:3984–3990. 2010. View Article : Google Scholar : PubMed/NCBI
5	Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, et al: The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell. 114:99–111. 2003. View Article : Google Scholar : PubMed/NCBI
6	Huang W, Zhang H, Davrazou F, Kutateladze TG, Shi X, Gozani O and Prestwich GD: Stabilized phosphatidylinositol-5-phosphate analogues as ligands for the nuclear protein ING2: Chemistry, biology and molecular modeling. J Am Chem Soc. 129:6498–6506. 2007. View Article : Google Scholar : PubMed/NCBI
7	Jones DR, Bultsma Y, Keune WJ, Halstead JR, Elouarrat D, Mohammed S, Heck AJ, D'Santos CS and Divecha N: Nuclear PtdIns5P as a transducer of stress signaling: An in vivo role for PIP4Kbeta. Mol Cell. 23:685–695. 2006. View Article : Google Scholar : PubMed/NCBI
8	Ythier D, Larrieu D, Binet R, Binda O, Brambilla C, Gazzeri S and Pedeux R: Sumoylation of ING2 regulates the transcription mediated by Sin3A. Oncogene. 29:5946–5956. 2010. View Article : Google Scholar : PubMed/NCBI
9	Nie J, Liu L, Wu M, Xing G, He S, Yin Y, Tian C, He F and Zhang L: HECT ubiquitin ligase smurf1 targets the tumor suppressor ING2 for ubiquitination and degradation. FEBS Lett. 584:3005–3012. 2010. View Article : Google Scholar : PubMed/NCBI
10	Sarker KP, Kataoka H, Chan A, Netherton SJ, Pot I, Huynh MA, Feng X, Bonni A, Riabowol K and Bonni S: ING2 as a novel mediator of transforming growth factor-beta-dependent responses in epithelial cells. J Biol Chem. 283:13269–13279. 2008. View Article : Google Scholar : PubMed/NCBI
11	Walzak AA, Veldhoen N, Feng X, Riabowol K and Helbing CC: Expression profiles of mRNA transcript variants encoding the human inhibitor of growth tumor suppressor gene family in normal and neoplastic tissues. Exp Cell Res. 314:273–285. 2008. View Article : Google Scholar
12	Saito M, Kumamoto K, Robles AI, Horikawa I, Furusato B, Okamura S, Goto A, Yamashita T, Nagashima M, Lee TL, et al: Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS One. 5:e155412010. View Article : Google Scholar : PubMed/NCBI
13	Nagashima M, Shiseki M, Miura K, Hagiwara K, Linke SP, Pedeux R, Wang XW, Yokota J, Riabowol K and Harris CC: DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci USA. 98:9671–9676. 2001. View Article : Google Scholar : PubMed/NCBI
14	Sironi E, Cerri A, Tomasini D, Sirchia SM, Porta G, Rossella F, Grati FR and Simoni G: Loss of heterozygosity on chromosome 4q32–35 in sporadic basal cell carcinomas: Evidence for the involvement of p33ING2/ING1L and SAP30 genes. J Cutan Pathol. 31:318–322. 2004. View Article : Google Scholar : PubMed/NCBI
15	Borkosky SS, Gunduz M, Nagatsuka H, Beder LB, Gunduz E, Ali MA, Rodriguez AP, Cilek MZ, Tominaga S, Yamanaka N, et al: Frequent deletion of ING2 locus at 4q35.1 associates with advanced tumor stage in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 135:703–713. 2009. View Article : Google Scholar
16	Cetin E, Cengiz B, Gunduz E, Gunduz M, Nagatsuka H, Bekir-Beder L, Fukushima K, Pehlivan D, N MO, Nishizaki K, et al: Deletion mapping of chromosome 4q22–35 and identification of four frequently deleted regions in head and neck cancers. Neoplasma. 55:299–304. 2008.
17	Zhang HK, Pan K, Wang H, Weng DS, Song HF, Zhou J, Huang W, Li JJ, Chen MS and Xia JC: Decreased expression of ING2 gene and its clinicopathological significance in hepato-cellular carcinoma. Cancer Lett. 261:183–192. 2008. View Article : Google Scholar
18	Ythier D, Brambilla E, Binet R, Nissou D, Vesin A, de Fraipont F, Moro-Sibilot D, Lantuejoul S, Brambilla C, Gazzeri S and Pedeux R: Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. Lung Cancer. 69:180–186. 2010. View Article : Google Scholar
19	Lu F, Dai DL, Martinka M, Ho V and Li G: Nuclear ING2 expression is reduced in human cutaneous melanomas. Br J Cancer. 95:80–86. 2006. View Article : Google Scholar : PubMed/NCBI
20	Kumamoto K, Fujita K, Kurotani R, Saito M, Unoki M, Hagiwara N, Shiga H, Bowman ED, Yanaihara N, Okamura S, et al: ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. Int J Cancer. 125:1306–1315. 2009. View Article : Google Scholar : PubMed/NCBI
21	Kumada T, Tsuneyama K, Hatta H, Ishizawa S and Takano Y: Improved 1-h rapid immunostaining method using intermittent microwave irradiation: Practicability based on 5 years application in Toyama medical and pharmaceutical university hospital. Mod Pathol. 17:1141–1149. 2004. View Article : Google Scholar : PubMed/NCBI
22	Cengiz BI, Gunduz E, Gunduz M, Beder LB, Tamamura R, Bagci C, Yamanaka N, Shimizu K and Nagatsuka H: Tumor-specific mutation and downregulation of ING5 detected in oral squamous cell carcinoma. Int J Cancer. 127:2088–2094. 2010. View Article : Google Scholar : PubMed/NCBI
23	Gong W, Russell M, Suzuki K and Riabowol K: Subcellular targeting of p33ING1b by phosphorylation-dependent 14–3–3 binding regulates p21WAF1 expression. Mol Cell Biol. 26:2947–2954. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yu L, Thakur S, Leong-Quong RY, Suzuki K, Pang A, Bjorge JD, Riabowol K and Fujita DJ: Src regulates the activity of the ING1 tumor suppressor. PLoS One. 8:e609432013. View Article : Google Scholar : PubMed/NCBI
25	Eapen SA, Netherton SJ, Sarker KP, Deng L, Chan A, Riabowol K and Bonni S: Identification of a novel function for the chromatin remodeling protein ING2 in muscle differentiation. PLoS One. 7:e406842012. View Article : Google Scholar : PubMed/NCBI
26	Larrieu D, Ythier D, Binet R, Brambilla C, Brambilla E, Sengupta S and Pedeux R: ING2 controls the progression of DNA replication forks to maintain genome stability. EMBO Rep. 10:1168–1174. 2009. View Article : Google Scholar : PubMed/NCBI
27	Goeman F, Otto K, Kyrylenko S, Schmidt O and Baniahmad A: ING2 recruits histone methyltransferase activity with methylation site specificity distinct from histone H3 lysines 4 and 9. Biochim Biophys Acta. 1783:1673–1680. 2008. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Wang J and Li G: Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Lett. 580:3787–3793. 2006. View Article : Google Scholar : PubMed/NCBI